title: Advanced non-small-cell lung cancer (NSCLC) treated with folinic acid (F), fluorouracil (FU), vincristine (O), and mitomycin-C (Mi), (F-FOMi).
abstract: Thirty-one patients with advanced non-small-cell lung cancer (NSCLC) were treated with a combination of folinic acid, fluorouracil, vincristine, and mitomycin (F-FOMi). Eight partial responses (26%), eight stable disease (26%), and 15 progressive disease (48%) were obtained. Patients with performance status (PS) 0-1 had a significantly better response rate than those with PS 2-3. Overall actuarial survival was 10 months. Toxicity was mild and mainly gastrointestinal with mucositis and diarrhea. F-FOMi seems to be comparable to regimens more widely used in the treatment of NSCLC.
authors.affiliation: Cattedra di Oncologia Medica, Università Cattolica del S. Cuore, Rome, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Barone
authors.forename: A
authors.initials: A
authors.lastname: Astone
authors.forename: A
authors.initials: A
authors.lastname: Cassano
authors.forename: M R
authors.initials: MR
authors.lastname: Noviello
authors.forename: T
authors.initials: T
authors.lastname: Fontana
authors.forename: E
authors.initials: E
authors.lastname: Ricevuto
authors.forename: A
authors.initials: A
authors.lastname: Grieco
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D016685:Mitomycin; D014750:Vincristine; D002955:Leucovorin; D005472:Fluorouracil